Clinical Trial Update: Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial (ReACT) evaluating risk-adapted therapy guided by circulating tumor HPV DNA in HPV-associated and HPV-positive oropharyngeal sq…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv-associated Oropharyngeal Squamous Cell Carcinoma
• Hpv-positive Oropharyngeal Squamous Cell Carcinoma

Snippet

Sponsor: Jonathan Schoenfeld, MD, MPH | Conditions: HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING